Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SeerSEER -0.95%54 EBITDA Margin % is -511.39% as of Jun. 2026. GuruFocus rates SEER with a GF Score™ of 54/100 and a GF Value™ of $2.02 (Fairly Valued). The stock has 8 warning signs investors should review. Among 943 Biotechnology companies, Seer ranks worse than 71.26% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Seer's EBITDA for the
three
months ended in Jun. 2026 was $-15.35 Mil. Seer's Revenue for the
three
months ended in Jun. 2026 was $3.00 Mil. Therefore, Seer's EBITDA margin for the quarter that ended in Jun. 2026 was -511.39%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Seer EBITDA Margin % Related Terms
Seer EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Seer's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SEER vs VANI, FBIO, PMN: EBITDA Margin % Comparison
For the Biotechnology subindustry, Seer's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Seer EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Seer's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Seer's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Seer (SEER) has a EBITDA Margin % of -511.39% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Seer and its competitors. According to the industry distribution chart, Seer ranks #672 out of 943 companies in the Biotechnology industry, placing it in the top 71.3%.
Is Seer's EBITDA Margin % too high?
Seer's current EBITDA Margin % is -511.39%. Based on the distribution chart, Seer ranks #672 out of 943 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Seer has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Seer's EBITDA Margin % compare to VANI and FBIO?
According to the Biotechnology industry distribution chart, Seer ranks #672 out of 943 companies for EBITDA Margin %. This places Seer in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Seer and its competitors. Seer's current EBITDA Margin % is -511.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seer stock overvalued right now?
Based on GuruFocus' analysis, Seer (SEER) is currently considered Fairly Valued. The stock's GF Value™ is $2.02, compared to a current price of $2.08 — trading 3% above its estimated fair value. The current EBITDA Margin % is -511.39%. Seer's overall GF Score™ is 54/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Seer (SEER), the current EBITDA Margin % is -511.39% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Seer (SEER) Overvalued in 2026?
Based on GuruFocus' analysis, Seer stock appears to be overvalued.
The current stock price of $2.08 is trading 3% above its estimated GF Value™ of $2.02.
GuruFocus considers Seer to be Fairly Valued.
Key valuation signals for SEER:
EBITDA Margin %: -511.39%
GF Value™: $2.02 vs. price of $2.08 (3% above fair value)
No single metric tells the full story. See the SEER stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.
54GF Score
Get the complete analysis for SEER
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SEER has been successfully added to your 
